Neuronetics, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $165.3M
- Price
- $2.17
- % Change (Daily % change from the live per-ticker quote feed.)
- -1.81%
- Volume
- 637.7K
About
Neuronetics, Inc. functions as a medical technology enterprise with commercialized products, specializing in the creation, enhancement, and global distribution of solutions for individuals experiencing neurohealth conditions, both within the U.S. and abroad. The company's flagship product is the NeuroStar Advanced Therapy System, an in-office, non-surgical, and non-pharmaceutical treatment option available for adult patients diagnosed with major depressive disorder. This sophisticated system utilizes transcranial magnetic stimulation (TMS) to generate a pulsed magnetic field, similar in strength to an MRI, which subsequently induces electrical currents. These currents are specifically engineered to activate brain areas that are key to mood regulation. Neuronetics distributes its offerings directly to psychiatrists through its dedicated sales and client support personnel. Established in 2001, the company's corporate headquarters are situated in Malvern, Pennsylvania.
Quick stats
Shares outstanding76.2M
Computed float44.9M
Float / shares58.9%
Cash runway (months)17.7
Key info
SectorHealthcare
IndustryMedical - Devices
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001227636
Websitehttps://www.neurostar.com
AI Summary
AI-generated1/20
minorbullishproduct launch
NeuroStar Advances Practice Innovation with First-Ever TMS Integration with an EHR/EMR System
Neuronetics (NASDAQ: STIM) announced the integration of its TrakStar practice management platform with AdvancedMD, a cloud EHR used by more than 65,000 practitioners across 13,000 independent practices, making NeuroStar the first TMS system to integrate with an EHR/EMR.
The integration will be available to NeuroStar providers already using AdvancedMD starting in Q4, routing treatment data into the same system practices use for scheduling, clinical records, and revenue cycle, and cutting duplicate documentation across a multi-session TMS course of care.
NeuroStar has treated more than 253,000 patients with over 9.1 million sessions nationwide; the tie-up gives AdvancedMD practices a lower-friction path to adding a TMS service line while giving NeuroStar a new adoption lever in practice platform decisions.